- Home
- HOFT vs TCRX Comparison
HOFT vs TCRX Comparison
Compare HOFT & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOFT
- TCRX
- Stock Information
- Founded
- HOFT 1924
- TCRX 2018
- Country
- HOFT United States
- TCRX United States
- Employees
- HOFT N/A
- TCRX N/A
- Industry
- HOFT Home Furnishings
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- HOFT Consumer Discretionary
- TCRX Health Care
- Exchange
- HOFT Nasdaq
- TCRX Nasdaq
- Market Cap
- HOFT 104.6M
- TCRX 90.5M
- IPO Year
- HOFT 1999
- TCRX 2021
- Fundamental
- Price
- HOFT $9.82
- TCRX $1.45
- Analyst Decision
- HOFT
- TCRX Strong Buy
- Analyst Count
- HOFT 0
- TCRX 6
- Target Price
- HOFT N/A
- TCRX $9.50
- AVG Volume (30 Days)
- HOFT 48.7K
- TCRX 774.8K
- Earning Date
- HOFT 06-12-2025
- TCRX 05-06-2025
- Dividend Yield
- HOFT 9.37%
- TCRX N/A
- EPS Growth
- HOFT N/A
- TCRX N/A
- EPS
- HOFT N/A
- TCRX N/A
- Revenue
- HOFT $397,465,000.00
- TCRX $4,421,000.00
- Revenue This Year
- HOFT $3.58
- TCRX $68.86
- Revenue Next Year
- HOFT $7.66
- TCRX $14.01
- P/E Ratio
- HOFT N/A
- TCRX N/A
- Revenue Growth
- HOFT N/A
- TCRX N/A
- 52 Week Low
- HOFT $7.34
- TCRX $1.02
- 52 Week High
- HOFT $19.79
- TCRX $9.29
- Technical
- Relative Strength Index (RSI)
- HOFT 55.02
- TCRX 49.42
- Support Level
- HOFT $8.98
- TCRX $1.33
- Resistance Level
- HOFT $9.74
- TCRX $1.49
- Average True Range (ATR)
- HOFT 0.43
- TCRX 0.11
- MACD
- HOFT 0.04
- TCRX 0.02
- Stochastic Oscillator
- HOFT 54.66
- TCRX 69.12
About HOFT Hooker Furnishings Corporation
Hooker Furnishings Corp is a designer, marketer and importer of casegoods (wooden and metal furniture), leather furniture, fabric-upholstered furniture, lighting, accessories, and home decor for the residential, hospitality and contract markets. It is also domestically manufactured premium residential custom leather, custom fabric-upholstered furniture, and outdoor furniture. The company operates in four segment Hooker Branded segment, Home Meridian segment, Domestic Upholstery segment and All Other.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.